SCHEMBL1361653

SCHEMBL1361653

OCCCc1oc(-n2cncn2)nc1-c1ccc(Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
ALDH1A1 P00352 3/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
PDE4B Q07343 1/20 0.36
CYP3A4 P08684 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
MAPT P10636 1/20 0.33
TLR8 Q9NR97 1/20 0.32
GRM7 Q14831 1/20 0.31
TSHR P16473 1/20 0.31
PRKAG1 P54619 1/20 0.31
PRKAA1 Q13131 1/20 0.31
PRKAB1 Q9Y478 1/20 0.31
APOBEC3A P31941 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
RXRA P19793 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7461986 0.84 RXRA (0.46) KDM4EALDH1A1PDE4BMAPTTSHR
SCHEMBL1361686 0.81 NOTUM (0.40) KDM4ECYP11B1CYP11B2ALDH1A1SIRT2
SCHEMBL7467327 0.80 KDM4E (0.40) KDM4EALDH1A1PDE4B
SCHEMBL1363245 0.80 GRM7 (0.40) KDM4EALDH1A1CYP3A4MAPTGRM7
SCHEMBL1361930 0.79 NOTUM (0.40) CYP11B1CYP11B2SIRT2SMN1; SMN2
SCHEMBL7462904 0.79 ALDH1A1 (0.43) KDM4ECYP11B1CYP11B2ALDH1A1CYP3A4
SCHEMBL7458927 0.78 ALDH1A1 (0.42) KDM4EALDH1A1PDE4BCYP3A4LMNA
SCHEMBL1363162 0.76 SIRT2 (0.49) KDM4ECYP11B1CYP11B2ALDH1A1SIRT2
SCHEMBL963990 0.73 SIRT2 (0.40) KDM4EALDH1A1SIRT2CYP3A4SMN1; SMN2
SCHEMBL7461994 0.70 ALDH1A1 (0.42) KDM4EALDH1A1PDE4BCYP3A4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067453-B2 Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-29 US disclosed
US-20080269219-A1 Neurotrophin production/secretion promoting agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-7396848-B1 oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-08 US disclosed
EP-1206472-B1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-10-01 EP disclosed
US-6605629-B1 Oxazole derivatives; low toxicity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269219-A1 Neurotrophin production/secretion promoting agent BDNF, NGF, NTRK2 KDM4E 4507/4885CYP11B1 179/4885CYP11B2 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.